Company profile for Gilgamesh Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Gilgamesh is a clinical stage biotech developing novel medicines that harness the therapeutic promise of psychedelics to revolutionize the treatment of mental illness Gilgamesh is a pioneering early-stage biotech developing novel compounds that build upon the benefits of classic psychedelics with improvements of other components such as safety, tolerability, duration, and efficacy. Mental health worldwide has reached epidemic...
Gilgamesh is a clinical stage biotech developing novel medicines that harness the therapeutic promise of psychedelics to revolutionize the treatment of mental illness Gilgamesh is a pioneering early-stage biotech developing novel compounds that build upon the benefits of classic psychedelics with improvements of other components such as safety, tolerability, duration, and efficacy. Mental health worldwide has reached epidemic proportions and novel treatments have not kept pace with the urgent need to treat depression, anxiety, drug addiction and many other devastating diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
113 University Place, Suite 1019, NY, NY 10003
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/abbvie-completes-acquisition-of-gilgamesh-pharmaceuticals-bretisilocin-302587587.html

PR NEWSWIRE
17 Oct 2025

https://www.pharmiweb.com/press-release/2025-10-15/enveric-biosciences-hires-ip-powerhouse-to-defend-its-us-patent-with-claims-relevant-to-bretisiloc

PHARMIWEB
15 Oct 2025

https://news.abbvie.com/2025-08-25-AbbVie-to-Acquire-Gilgamesh-Pharmaceuticals-Bretisilocin,-a-Novel,-Investigational-Therapy-for-Major-Depressive-Disorder,-Expanding-Psychiatry-Pipeline

PRESS RELEASE
26 Aug 2025

https://www.reuters.com/legal/transactional/abbvie-talks-acquire-gilgamesh-pharmaceuticals-bloomberg-news-reports-2025-07-30/

REUTERS
31 Jul 2025

https://www.prnewswire.com/news-releases/gilgamesh-pharmaceuticals-announces-positive-topline-phase-2a-results-for-gm-2505-in-major-depressive-disorder-mdd-302465404.html

PR NEWSWIRE
27 May 2025
AbbVie pens $2B+ next-gen psychedelic pact with Gilgamesh
AbbVie pens $2B+ next-gen psychedelic pact with Gilgamesh

14 May 2024

// Gabrielle Masson FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/abbvie-joins-psychedelic-push-inks-2b-next-gen-neuro-deal-gilgamesh

Gabrielle Masson FIERCE BIOTECH
14 May 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty